NewGenGene Therapeutics

NewGenGene Therapeutics is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of next-generation adeno-associated virus (AAV) gene therapies. The company leverages its proprietary NGG-AAV platform to engineer vectors with enhanced tissue specificity and reduced immunogenicity for treating rare genetic diseases and neurodegenerative conditions. Its lead candidate, NGG-101, is an AAV-based gene therapy currently undergoing Phase 1/2 clinical evaluation for Hemophilia B. Beyond hematology, NewGenGene is advancing a diverse pipeline targeting lysosomal storage disorders like Pompe disease and CNS indications such as Parkinson's disease. The firm is backed by prominent life science investors, including Qiming Venture Partners and Lilly Asia Ventures.